Timothy P. Cripe

Biochemistry, Genetics and Molecular Biology · Life Sciences

54h-index8.2kcitations359works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(140), CAR-T cell therapy research(73), Neuroblastoma Research and Treatments(72), Herpesvirus Infections and Treatments(38), Sarcoma Diagnosis and Treatment(36)

Publications357 total

Trabectedin decreases myeloid resistance to improve the efficacy of anti-PD1 immunotherapy and delay glioma malignant progression
Molecular Therapy Oncology·2026Open Access
Cell-based potency assay for anti-CD3-anti-CD19 diabody
Journal of Immunological Methods·2025
650 Enhanced cytotoxicity of anti-ROR1 CAR NK cells against glioblastoma via combined treatment with oncolytic virus and NKTR-255
Regular and Young Investigator Award Abstracts·2025Open Access
Development of VNX-101, an adeno-associated virus with less immunogenicity and efficient long-term expression of a CD19 T cell engager
Molecular Therapy — Methods & Clinical Development·2025Open Access
Local Control and Toxicity Outcomes After Stereotactic Body Radiation Therapy for Metastatic Osteosarcoma in Pediatric Patients
Pediatric Blood & Cancer·2025· 3 citedOpen Access
Patient-centered long-term follow-up for gene therapies aligns with ethics and science
Molecular Therapy·2025· 1 cited
Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody
2025Open Access
Clinical Trials or FDA-Approved Therapies? The Ethics of Sickle Cell Gene Therapy Access
The American Journal of Bioethics·2025
Figure 3 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2025Open Access
Figure 6 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2025Open Access
Supplementary Table S2 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2025Open Access
Figure 5 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2025Open Access
Supplementary Figure S6 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2025Open Access
Supplementary Table S3 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2025Open Access
Figure 1 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2025Open Access
Supplementary Figure S7 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2025Open Access
Supplementary Figure S4 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2025Open Access
Supplementary Table S4 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2025Open Access
Data from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2025Open Access
Figure 4 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2025Open Access
page 1 of 18Next →

Frequent Co-authors

Nancy Ratner(10), Mark A. Currier(7), Yonatan Y. Mahller(7), Margaret H. Collins(6), Jianqiang Wu(5), Mi‐Ok Kim(5), Balveen Kaur(5), Thomas H. Haugen(4), L P Turek(4), Edwin Jousma(4), David Eaves(4), Chun‐Yu Chen(4), E. Antonio Chiocca(4), Shyra J. Miller(3), Tilat A. Rizvi(3), Eva Dombi(3), Mary Frances Wedekind(3), José A. Cancelas(3), Keri A. Streby(3), Joe Conner(3)